06.04.24 -- The Anti-CDMO With CTMC's Jason Bock, Ph.D. And KSQ's Thomas Leitch

Building strong relationships with CDMOs and CROs relies on a solid outsourcing framework. Review three key areas that should be built into your outsourcing framework and agreements.

Improving your ADC’s chance of clinical success requires an understanding of what potential obstacles lie ahead and what capabilities and expertise are necessary to overcome them.

Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.

The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.

Explore how a novel conjugation technology is enabling streamlined and cost-efficient production of antibody-drug conjugates (ADCs), driving the development of effective targeted cancer therapies.

Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

Capacity constraints typically are accompanied by other challenges, including missed timelines, defect rates, and overall decreased satisfaction with pharma companies’ bioprocessing CDMOs.

Achieve your therapeutic and commercial goals by utilizing a tried-and-tested standardized approach combined with the latest technology and reliable analytics.

As developers begin their AAV therapy research, opting to conduct early phase studies with an experienced CDMO can help mitigate funding challenges and procure material for data generation.